Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics

References

• Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. Cleve Clin J Med. 2012;79(1):57–66.
   PubMed Web of Science ®Google Scholar
• Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve Clin J Med. 2007;74(Suppl_4):S21–28.
   PubMedGoogle Scholar
• US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. US Food and Drug Administration, Washington, DC: http://www.fda.gov/downloads/Drugs/./Guidances/ucm071185.pdf. Accessed September 20, 2017.
   Google Scholar
• Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29(2):109–115. Accessed September 20, 2017.
   PubMed Web of Science ®Google Scholar
• Loewen K, Schreiber Y, Kirlew M, et al. Community-associated methicillin-resistant Staphylococcus aureus infection: literature review and clinical update. Can Fam Physician. 2017;63(7):512–520.
   PubMed Web of Science ®Google Scholar
• King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144(5):309–317.
   PubMed Web of Science ®Google Scholar
• Dryden M, Andrasevic AT, Bassetti M, et al. Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey. Int J Antimicrob Agents. 2015;45(Suppl 1):S1–S14.
   PubMedGoogle Scholar
• Chen CJ, Huang YC. New epidemiology of Staphylococcus aureus infection in Asia. Clin Microbiol Infect. 2014;20(7):605–623.
   PubMed Web of Science ®Google Scholar
• Song J-H, Hsueh P-R, Chung DR, et al. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother. 2011;66(5):1061–1069.
   PubMed Web of Science ®Google Scholar
• Hersh AL et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168(14):1585–1591.
   PubMed Web of Science ®Google Scholar
• Ray GT, Suaya JA, Incidence BR. microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis. 2013;13:252.
   PubMed Web of Science ®Google Scholar
• Chou Y-H, Lee M-S, Lin R-Y, Wu C-Y, et al. Risk factors for methicillin-resistant Staphylococcus aureus skin and soft-tissue infections in outpatients in Taiwan. Epidemiol Infect. 2015;143(04):749–753.
   PubMedGoogle Scholar
• Yamaguchi T, Okamura S, Miura Y, Koyama S, Yanagisawa H, Matsumoto T. Molecular characterization of community-associated methicillin-resistant Staphylococcus aureus isolated from skin and pus samples of outpatients in Japan. Microb Drug Resist. 2015;21(4):441–447.
   PubMed Web of Science ®Google Scholar
• Pl H, Chuang SK, Choi YF, et al. Community-associated methicillin-resistant and methicillin-sensitive Staphylococcus aureus: skin and soft tissue infections in Hong Kong. Diagn Microbiol Infect Dis. 2008;61(3):245–250.
   PubMed Web of Science ®Google Scholar
• Noh JY, Cheong HJ, Song JY, et al. Skin and soft tissue infections: experience over a five-year period and clinical usefulness of ultrasonography-guided gun biopsy-based culture. Scand J Infect Dis. 2011;43(11–12):870–876.
   PubMed Web of Science ®Google Scholar
• Phakade RS, Nataraj G, Kuyare SS, et al. Is methicillin-resistant Staphylococcus aureus involved in community acquired skin and soft tissue infections? Experience from a tertiary care centre in Mumbai. J Postgrad Med. Jan. 2012;58(1):3–7.
   PubMed Web of Science ®Google Scholar
• Li X, Chen Y, Gao W, et al. Epidemiology and outcomes of complicated skin and soft tissue infections among inpatients in Southern China from 2008 to 2013. PLoS One. 2016;11(2):e0149960.
   PubMed Web of Science ®Google Scholar
• Hsu L-Y, Tan T-Y, Jureen R, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis. 2007;13(12):1944–1947.
   PubMed Web of Science ®Google Scholar
• Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 2007;57(1):7–13.
   PubMed Web of Science ®Google Scholar
• Cai Y, Venkatachalam I, Tee NW, et al. Prevalence of healthcare-associated infections and antimicrobial use among adult inpatients in Singapore acute-care hospitals: results from the first national point prevalence survey. Clin Infect Dis. 2017;64(Suppl_2):S61–S67.
   PubMedGoogle Scholar
• Chan KS, Ling ML, Hsu LY, Tan AL. Methicillin-resistant Staphylococcus aureus throat colonization among healthcare workers during an outbreak in Singapore General Hospital. Infect Control Hosp Epidemiol. 2009;30(1):95–97.
   PubMed Web of Science ®Google Scholar
• Hsu L-Y, Loomba-Chlebicka N, Koh Y-L, et al. Evolving EMRSA-15 epidemic in Singapore hospitals. J Med Microbiol. 2007;56(3):376–379.
   PubMed Web of Science ®Google Scholar
• Win M-K, Soliman TAA, Lee LK, et al. Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore. BMC Infect Dis. 2015;15(1):391.
   PubMedGoogle Scholar
• Turina M, Cheadle WG. Clinical challenges and unmet needs in the management of complicated skin and skin structure, and soft tissue infections. Surg Infect. 2005;6(s2):s-23–20.
   PubMedGoogle Scholar
• Peterson LR. A review of tigecycline – the first glycylcycline. Int J Antimicrob Agents. 2008;32(Suppl 4):S215–S222.
   PubMedGoogle Scholar
• Lipsky BA, Tabak YP, Johannes RS, et al. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia. 2010;53(5):914–923.
   PubMed Web of Science ®Google Scholar
• Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(Suppl 3):iii35–iii44.
   PubMed Web of Science ®Google Scholar
• Stenstrom R, Grafstein E, Romney M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in a Canadian emergency department. CJEM. 2009;11(05):430–438.
   PubMedGoogle Scholar
• Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J. 2008;27(1):1–7.
   PubMed Web of Science ®Google Scholar
• Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2000;44(6):1549–1555.
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292.
   PubMed Web of Science ®Google Scholar
• Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis. 2007;44(4):471–482.
   PubMed Web of Science ®Google Scholar
• D’Agata EM, Webb GF, Horn MA, Moellering RC, Ruan S. Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals. Clin Infect Dis. 2009;48(3):274–284.
   PubMed Web of Science ®Google Scholar
• Eron LJ et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52(90001):i3–i17.
   PubMedGoogle Scholar
• Bassetti M, Baguneid M, Bouza E, Dryden M, Nathwani D, Wilcox M. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20 (Suppl 4):3–18.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Eisenberg DF, Fang C, Miller LG, et al. Skin and soft tissue infections and associated complications among commercially insured patients aged 0–64 years with and without diabetes in the U.S. PLoS One. 2013;8(4):e60057.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Chaudhari P, Nathanson BH, et al. Development and validation of a bedside risk score for MRSA among patients hospitalized with complicated skin and skin structure infections. BMC Infect Dis. 2012;12(1):154.
   PubMedGoogle Scholar
• Enoch S, Price P. Should alternative endpoints be considered to evaluate outcomes in chronic recalcitrant wounds. World Wide Wounds. 2004. Available from: http://www.worldwidewounds.com/2004/october/Enoch-Part2/Alternative-Enpoints-To-Healing.html. Accessed September 20, 2017.
   Google Scholar
• Napolitano LM. Severe soft tissue ifections. Infect Dis Clin North Am. 2009;23(3):571–591.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–e52.
   PubMed Web of Science ®Google Scholar
• Pan A, Cauda R, Concia E, et al. Consensus document on controversial issues in the treatment of complicated skin and skin-structure infections. Int J Infect Dis. 2010;14(Suppl 4):S39–S53.
   PubMedGoogle Scholar
• Kujath P, Kujath C. Complicated skin structure and soft tissue infections – are we threatened by multi-resistant pathogens? Eur J Med Res. 2010;15(12):544–553.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence Surgical site infection prevention and treatment of surgical site infection. 2013. Available from: https://www.nice.org.uk/guidance/qs49/resources/surgical-site-infection-2098675107781. Accessed September 20, 2017.
   Google Scholar
• Figtree M, Konecny P, Jennings Z, et al. Risk stratification and outcome of cellulitis admitted to hospital. J Infect. 2010;60(6):431–439.
   PubMed Web of Science ®Google Scholar
• Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44(6):777–784.
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008;29(2):160–169.
   PubMed Web of Science ®Google Scholar
• Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol. 2012;50(2):238–245.
   PubMed Web of Science ®Google Scholar
• Fish DN. Meropenem in the treatment of complicated skin and soft tissue infections. Ther Clin Risk Manag. 2006;2(4):401–415.
   PubMedGoogle Scholar
• Frewin DB, Bartholomeusz RCA, Gaffney RD, et al. A comparison of the effect of lisinopril and hydrochlorothiazide on electrolyte balance in essential hypertension. Eur J Clin Pharmacol. 1992;42(5):487–490.
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Klein N, Frossard M, et al. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin Pharmacol Ther. 2001;70(6):532–539.
   PubMed Web of Science ®Google Scholar
• Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45(6):1843–1846.
   PubMed Web of Science ®Google Scholar
• Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother. 2006;50(4):1372–1375.
   PubMed Web of Science ®Google Scholar
• Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res. 2010;15(12):554–563.
   PubMed Web of Science ®Google Scholar
• Hermsen ED, Hanson M, Sankaranarayanan J, et al. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010;9(1):9–14.
   PubMed Web of Science ®Google Scholar
• Hyun DY, Mason EO, Forbes A, et al. Trimethoprim-sulfamethoxazole or clindamycin for treatment of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J. 2009;28(1):57–59.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Roussos N, Gkegkes ID, et al. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009;18(7):921–944.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000;44(12):3408–3413.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481–1490.
   PubMed Web of Science ®Google Scholar
• Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin. 2010;26(2):407–421.
   PubMed Web of Science ®Google Scholar
• Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199(6):804–816.
   PubMed Web of Science ®Google Scholar
• Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59(Suppl 1):S59–S74.
   PubMed Web of Science ®Google Scholar
• Seaton RA, Gonzalez-Ruiz A, Cleveland KO, et al. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016;15(1):18.
   PubMedGoogle Scholar
• Nathwani D. New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents. 2009;34(Suppl 1):S24–S29.
   PubMedGoogle Scholar
• Davis SL, Mckinnon PS, Hall LM, et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy. 2007;27(12):1611–1618.
   PubMed Web of Science ®Google Scholar
• Owens RC, Lamp KC, Friedrich LV, Russo R, et al. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med. 2007;120(10):S6–S12.
   PubMed Web of Science ®Google Scholar
• Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother. 2008;62(Suppl 3): iii15–iii23.
   PubMedGoogle Scholar
• Gonzalez-Ruiz A, Seaton RA, Hamed K. Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections. Infect Drug Resist. 2016;9:47–58.
   PubMed Web of Science ®Google Scholar
• David MZ, Dryden M, Gottlieb T, et al. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new. Int J Antimicrob Agents. 2017;50(3):303–307.
   PubMed Web of Science ®Google Scholar
• Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis. 2013;76(1):61–68.
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–650.
   PubMed Web of Science ®Google Scholar
• Panagiotidis G, Backstrom T, Asker-Hagelberg C, et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother. 2010;54(5):1811–1814.
   PubMed Web of Science ®Google Scholar
• Chen HH, Hon PY, Hsu LY. Ceftaroline –an anti-MRSA cephalosporin and its implications for Singapore. Ann Acad Med Singapore. 2014;43(3):177–186.
   PubMed Web of Science ®Google Scholar
• Esposito S, Bassetti M, Concia E, et al. Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. J Chemother. 2017;29(4):197–214.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59(2):864–871.
   PubMed Web of Science ®Google Scholar
• Coyle EA, Cha R, Rybak MJ. Influences of linezolid, penicillin, and clindamycin, alone and in combination, on Streptococcal pyrogenic exotoxin A release. Antimicrob Agents Chemother. 2003;47(5):1752–1755.
   PubMed Web of Science ®Google Scholar
• Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254–262.
   PubMed Web of Science ®Google Scholar
• Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180–2190.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179.
   PubMed Web of Science ®Google Scholar
• Roberts KD, Sulaiman RM, Rybak MJ. Dalbavancin and oritavancin: an innovative approach to the treatment of Gram-positive infections. Pharmacotherapy. 2015;35(10):935–948.
   PubMed Web of Science ®Google Scholar
• Dryden M, Saeed K, Townsend R, et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother. 2012;67(9):2289–2296.
   PubMed Web of Science ®Google Scholar
• Bamford KB, Desai M, Aruede MJ, et al. Patients’ views and experience of intravenous and oral antimicrobial therapy: room for change. Injury. 2011;42(Suppl 5):S24–S27.
   PubMedGoogle Scholar
• Lee SL, Azmi S, Wong PS. Clinicians’ knowledge, beliefs and acceptance of intravenous-to-oral antibiotic switching, Hospital Pulau Pinang. Med J Malaysia. 2012;67(2):190–198.
   PubMedGoogle Scholar
• Mertz D, Koller M, Haller P, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009;64(1):188–199.
   PubMed Web of Science ®Google Scholar
• Masterton RG. Antibiotic de-escalation. Crit Care Clin. 2011;27(1):149–162.
   PubMed Web of Science ®Google Scholar
• Ohji G, Doi A, Yamamoto S, Iwata K. Is de-escalation of antimicrobials effective? A systematic review and meta-analysis. Int J Infect Dis. 2016;49:71–79.
   PubMed Web of Science ®Google Scholar
• Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. Infection. 2011;39(4):319–325.
   PubMed Web of Science ®Google Scholar
• Morel J, Casoetto J, Jospé R, et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care. 2010;14(6):R225.
   PubMed Web of Science ®Google Scholar
• de With K, Allerberger F, Amann S, et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection. 2016;44(3):395–439.
   PubMed Web of Science ®Google Scholar
• Liang SY, Kumar A. Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance. Curr Infect Dis Rep. 2015;17(7):493–493.
   PubMed Web of Science ®Google Scholar
• Loo LW, Liew YX, Lee W, et al. Impact of Antimicrobial Stewardship Program (ASP) on outcomes in patients with acute bacterial skin and skin structure infections (ABSSSIs) in an acute-tertiary care hospital. Infect Dis Ther. 2015;4(S1):15–25.
   PubMedGoogle Scholar
• Piacenti FJ, Leuthner KD. Antimicrobial stewardship and Clostridium difficile – associated diarrhea. J Pharm Pract. 2013;26(5):506–513.
   PubMedGoogle Scholar
• Macdougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005;18(4):638–656.
   PubMed Web of Science ®Google Scholar
• Doron S, Davidson LE. Antimicrobial sStewardship. Mayo Clin Proc. 2011;86(11):1113–1123.
   PubMed Web of Science ®Google Scholar
• Ashiru-Oredope D, Sharland M, Charani E, et al. Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart – Then Focus. J Antimicrob Chemother. 2012;67(Suppl 1):i51–i63.
   PubMedGoogle Scholar
• World Health Organization. Global action plan on antimicrobial resistance. Draft resolution with amendments resulting from informal consultations. In: World Health Organization Sixty-Eighth World Health Assembly; May 25, 2015; Geneva, Switzerland.
   Google Scholar
• Public Health Wales. Antimicrobial stewardship: “Start Smart– Then Focus”: Guidance for antimicrobial stewardship for hospitals in Wales; 2011. Available from: http://www.wales.nhs.uk/sitesplus/documents/888/Public%20Health%20Wales%20Antimicrobial%20Stewardship%20Guidance.pdf. Accessed September 20, 2017.
   Google Scholar
• Gilchrist M, Wade P, Ashiru-Oredope D, et al. Antimicrobial stewardship from policy to practice: experiences from UK antimicrobial pharmacists. Infect Dis Ther. 2015;4(Suppl 1):51–64.
   PubMedGoogle Scholar
• Talpaert MJ, Gopal Rao G, Cooper BS, et al. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother. 2011;66(9):2168–2174.
   PubMed Web of Science ®Google Scholar
• Loo LW, Liew YX, Lee W, Chlebicki P, Kwa AL. Impact of Antimicrobial Stewardship Program (ASP) on outcomes in patients with acute bacterial skin and skin structure infections (ABSSSIs) in an acute-tertiary care hospital. Infect Dis Ther. 2015;4(Suppl 1):15–25.
   PubMedGoogle Scholar
• Yao K, Bae L, Yew WP. Post-operative wound management. Aust Fam Physician. 2013;42(12):867–870.
   PubMedGoogle Scholar
• Sood A, Granick MS, Tomaselli NL. Wound dressings and comparative effectiveness data. Adv Wound Care. 2014;3(8):511–529.
   PubMedGoogle Scholar
• Sibbald RG, Mahoney J. A consensus report on the use of vacuum-assisted closure in chronic, difficult-to-heal wounds. Ostomy Wound Manage. 2003;49(11):52–66.
   PubMedGoogle Scholar
• Expert Working Group. Vacuum assisted closure: recommendations for use. A consensus document. Int Wound J. 2008;5(Suppl 4):iii-19.
   Google Scholar
• Henderson V, Timmons J, Hurd T. NPWT in everyday practice made easy. Wounds International. 2010;1(5):1–6.
   Google Scholar
• White RJ, Cooper R, Kingsley A. Wound colonization and infection: the role of topical antimicrobials. Br J Nurs. 2001;10(9):563–578.
   PubMedGoogle Scholar
• Abboud EC, Settle JC, Legare TB, et al. Silver-based dressings for the reduction of surgical site infection: review of current experience and recommendation for future studies. Burns. 2014;40(Suppl 1):S30–S39.
   PubMedGoogle Scholar
• Edwards-Jones V. Antimicrobial and barrier effects of silver against methicillin-resistant Staphylococcus aureus. J Wound Care. 2006;15(7):285–290.
   PubMedGoogle Scholar
• Halim AS, Khoo TL, Saad AZM. Wound bed preparation from a clinical perspective. Indian J Plast Sug. 2012;45(2):193–202.
   PubMedGoogle Scholar
• Alimov V, Lovecchio F, Sinha M, Foster KN, Drachman D. Use of a silver-containing hydrofiber dressing for filling abscess cavity following incision and drainage in the emergency department: a randomized controlled trial. Adv Skin Wound Care. 2013;26(1):20–25.
   PubMed Web of Science ®Google Scholar
• Krieger BR, Davis DM, Sanchez JE, et al. The use of silver nylon in preventing surgical site infections following colon and rectal surgery. Dis Colon Rectum. 2011;54(8):1014–1019.
   PubMed Web of Science ®Google Scholar
• White R, Cutting F. Modern exudate management: a review of wound treatments. World Wide Wounds. 2006. Available form: http://www.worldwidewounds.com/2006/september/White/Modern-Exudate-Mgt. Accessed September 20, 2017.
   Google Scholar
• Karr JC, de Mola FL, Pham T, Tooke L. Wound healing and cost-saving benefits of combining negative-pressure wound therapy with silver. Adv Skin Wound Care. 2013;26(12):562–565.
   PubMed Web of Science ®Google Scholar
• Dryden MS. Novel antibiotic treatment for skin and soft tissue infection. Curr Opin Infect Dis. 2014;27(2):116–124.
   PubMed Web of Science ®Google Scholar
• Davis JS, Sud A, O’Sullivan MVN, et al. Combination of vancomycin and β-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173–180.
   PubMed Web of Science ®Google Scholar
• Mcconeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia. Clin Infect Dis. 2013;57(12):1760–1765.
   PubMed Web of Science ®Google Scholar
• Russo A, Concia E, Cristini F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect. 2016;22(Suppl 2):S27–S36.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Carnelutti A. New therapeutic options for skin and soft tissue infections. Curr Opin Infect Dis. 2016;29(2):99–108.
   PubMed Web of Science ®Google Scholar
• May AK. Skin and soft tissue infections: the new surgical infection society guidelines. Surg Infect (Larchmt). 2011;12(3):179–184.
   PubMed Web of Science ®Google Scholar
• Esposito S, Bassetti M, Borre S, et al. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J Chemother. 2011 Oct;23(5):251–262.
   PubMed Web of Science ®Google Scholar
• Mensa J, Soriano A, Llinares P, et al. [Guidelines for antimicrobial treatment of the infection by Staphylococcus aureus]. Rev Esp Quimioter. 2013;26 Suppl 1:1–84.
   Google Scholar
• Gould FK, Brindle R, Chadwick PR, et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother. 2009;63(5):849–861.
   PubMed Web of Science ®Google Scholar
• White B, Seaton RA. Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin. Infect Drug Resist. 2011;4:115–127.
   PubMedGoogle Scholar
• Zyvox (linezolid, Pfizer Inc., USA) [Singapore product information]. 2008.
   Google Scholar
• Cubicin (daptomycin, MSD Pharma Pte Ltd, Singapore) [Singapore product information]. 2017.
   Google Scholar
• Tygacil (tigecycline, Wyeth, USA). [Singapore product information]. 2016.
   Google Scholar
• Zinforo (ceftaroline, AstraZeneca AB, Sweden.) [Singapore product information]. 2016.
   Google Scholar
• Sivextro (tedizolid), Bayer (South East Asia) Pte Ltd, Singapore [Singapore product information]. 2016.
   Google Scholar